443 related articles for article (PubMed ID: 31774054)
1. Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.
Buchert R; Buhmann C; Apostolova I; Meyer PT; Gallinat J
Dtsch Arztebl Int; 2019 Nov; 116(44):747-754. PubMed ID: 31774054
[TBL] [Abstract][Full Text] [Related]
2. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.
Sixel-Döring F; Liepe K; Mollenhauer B; Trautmann E; Trenkwalder C
J Neurol; 2011 Dec; 258(12):2147-54. PubMed ID: 21547379
[TBL] [Abstract][Full Text] [Related]
3. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
4. The role of DAT-SPECT in movement disorders.
Kägi G; Bhatia KP; Tolosa E
J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):5-12. PubMed ID: 20019219
[TBL] [Abstract][Full Text] [Related]
5. Explainable AI to improve acceptance of convolutional neural networks for automatic classification of dopamine transporter SPECT in the diagnosis of clinically uncertain parkinsonian syndromes.
Nazari M; Kluge A; Apostolova I; Klutmann S; Kimiaei S; Schroeder M; Buchert R
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1176-1186. PubMed ID: 34651223
[TBL] [Abstract][Full Text] [Related]
6. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.
Poewe W; Scherfler C
Mov Disord; 2003 Oct; 18 Suppl 7():S16-21. PubMed ID: 14531041
[TBL] [Abstract][Full Text] [Related]
7. [Recommendation for the differentiated use of nuclear medical diagnostic for parkinsonian syndromes].
van Eimeren T; Claßen J; Drzezga A; Eggers C; Hilker-Roggendorf R; Klucken J; Koschel J; Meyer PT; Redecker C; Theis H; Buhmann C
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):609-619. PubMed ID: 32957144
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.
Ba F; Martin WR
Parkinsonism Relat Disord; 2015 Feb; 21(2):87-94. PubMed ID: 25487733
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [
Wallert E; Letort E; van der Zant F; Winogrodzka A; Berendse H; Beudel M; de Bie R; Booij J; Raijmakers P; van de Giessen E
EJNMMI Res; 2022 Oct; 12(1):68. PubMed ID: 36273088
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans.
Vlaar AM; de Nijs T; van Kroonenburgh MJ; Mess WH; Winogrodzka A; Tromp SC; Weber WE
BMC Neurol; 2008 Nov; 8():42. PubMed ID: 18992168
[TBL] [Abstract][Full Text] [Related]
11. IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement.
Derlin T; Afzal W; Wilke F; Apostolova I; Klutmann S; Meyer PT; Buhmann C; Hesse S; Buchert R
Nuklearmedizin; 2010; 49(4):139-47. PubMed ID: 20502846
[TBL] [Abstract][Full Text] [Related]
12. Neuroimaging in Parkinsonian Disorders.
Tripathi M; Kumar A; Bal C
Neurol India; 2018; 66(Supplement):S68-S78. PubMed ID: 29503329
[TBL] [Abstract][Full Text] [Related]
13. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Thobois S; Guillouet S; Broussolle E
Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
[TBL] [Abstract][Full Text] [Related]
14. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.
Hellwig S; Amtage F; Kreft A; Buchert R; Winz OH; Vach W; Spehl TS; Rijntjes M; Hellwig B; Weiller C; Winkler C; Weber WA; Tüscher O; Meyer PT
Neurology; 2012 Sep; 79(13):1314-22. PubMed ID: 22914831
[TBL] [Abstract][Full Text] [Related]
15. Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT.
Takaya S; Sawamoto N; Okada T; Okubo G; Nishida S; Togashi K; Fukuyama H; Takahashi R
Parkinsonism Relat Disord; 2018 Feb; 47():15-21. PubMed ID: 29157745
[TBL] [Abstract][Full Text] [Related]
16. The role of molecular imaging in the differential diagnosis of parkinsonism.
Booij J; Teune LK; Verberne HJ
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):17-26. PubMed ID: 22460157
[TBL] [Abstract][Full Text] [Related]
17. The utility of FDG-PET in the differential diagnosis of Parkinsonism.
Brajkovic L; Kostic V; Sobic-Saranovic D; Stefanova E; Jecmenica-Lukic M; Jesic A; Stojiljkovic M; Odalovic S; Gallivanone F; Castiglioni I; Radovic B; Trajkovic G; Artiko V
Neurol Res; 2017 Aug; 39(8):675-684. PubMed ID: 28378615
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.
Vlaar AM; van Kroonenburgh MJ; Kessels AG; Weber WE
BMC Neurol; 2007 Sep; 7():27. PubMed ID: 17764571
[TBL] [Abstract][Full Text] [Related]
19. Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study.
Tsang K; Walker R
J Neurol; 2023 May; 270(5):2550-2558. PubMed ID: 36795149
[TBL] [Abstract][Full Text] [Related]
20. Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison.
Hellwig S; Reinhard M; Amtage F; Guschlbauer B; Buchert R; Tüscher O; Weiller C; Niesen WD; Meyer PT
Eur J Neurol; 2014 Jun; 21(6):860-6. PubMed ID: 24602186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
